Jaeb Center for Health Research
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jaeb Center for Health Research sits in the top decile of US sponsors by registered trial count (#218 of 15,742 sponsors by registered trial count).
Jaeb Center for Health Research: 119 sponsored US clinical trials, 17 recruiting.
Jaeb Center for Health Research sponsors 119 registered US clinical trials on ClinicalTrials.gov, 17 of them currently recruiting, and 89 completed. 53 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Amblyopia, with 9 trials.
Top-decile sponsor footprint
Jaeb Center for Health Research ranks in the top decile of sponsors by registered trial count (#218 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
89 of 95 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
119 total, page 2 of 3
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
NCT02660242
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
NCT02411578
A Prospective Observational Study of Adult Strabismus
NCT02510040
Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms
NCT02438189
Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
NCT02390531
A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes
NCT02258373
A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia
NCT02223650
Study of Binocular Computer Activities for Treatment of Amblyopia
NCT02200211
Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use
NCT02137512
Phase II Combination Steroid and Anti-VEGF for Persistent DME
NCT01945866
Insulin Clamp Ancillary Study for Assessment of Insulin Resistance
NCT02045290
Treatment for CI-DME in Eyes With Very Good VA Study
NCT01909791
Metformin Therapy for Overweight Adolescents With Type 1 Diabetes
NCT01881828
Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children
NCT01823341
Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study
NCT01591681
Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
NCT01627249
Convergence Insufficiency Treatment Study (CITS)
NCT01515943
Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01489189
Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation
NCT01515475
An Outpatient Pump Shutoff Pilot Feasibility and Safety Study
NCT01736930
Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control
NCT01323348
NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
NCT01331005
Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System
NCT01271023
Levodopa for the Treatment of Residual Amblyopia
NCT01190813
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
NCT00760526
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
NCT00891995
Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia
NCT01032603
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
NCT00996437
Observation Versus Occlusion Therapy for Intermittent Exotropia
NCT01032330
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
NCT00944710
Increasing Patching for Amblyopia in Children 3 to < 8 Years Old
NCT00945100
Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia
NCT00789672
Immediate Office Probing vs Deferred Facility Probing for Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old
NCT00780741
Continuous Glucose Sensor Profiles in Non-Diabetic Subjects
NCT00717977
Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old
NCT00669539
Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia
NCT00587171
A Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes
NCT00607503
Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children
NCT00525174
Combined Patching-Atropine for Residual Amblyopia
NCT00506675
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
NCT00445003
Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
NCT00444600
The Course of Response to Focal Photocoagulation for DME
NCT00442156
Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
NCT00406133
Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors
NCT00607139
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
NCT00336323
Effect of the Fat Content of the Bedtime Snack on Overnight Hypoglycemia
NCT00493935
Pilot Study of the Navigator Continuous Glucose Monitor
NCT00166673
Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds
NCT00315328
Evaluation of Vitrectomy for Diabetic Macular Edema
NCT00709319
The Effect of Insulin During Exercise on the Development of Low Blood Sugar in Individuals With Type I Diabetes
NCT00147342
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 18 |
| Phase 3 | 46 |
| Phase 4 | 7 |
Where Jaeb Center for Health Research enrollment is open (later-stage tilt)
17 recruiting of 119 indexed (14% open); 89 completed (75%).
Phase mix: 53 late (III/IV) vs 21 early (I/II) (later-stage heavy).
Top condition: Amblyopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jaeb Center for Health Research: open-pipeline peers nationwide
Peers matched on 119 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Jaeb Center for Health Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 119 trials (± recruiting share)
- Children's Hospital Los Angeles · 119 trials · 29% recruiting
- Medtronic - MITG · 119 trials · 4% recruiting
- Michigan State University · 120 trials · 20% recruiting
- San Diego State University · 118 trials · 27% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Jaeb Center for Health Research page
119 registered trials is a research-attention snapshot, not an endorsement of Jaeb Center for Health Research or any single study.
- 17 of Jaeb Center for Health Research's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Amblyopia is the condition Jaeb Center for Health Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Amblyopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jaeb Center for Health Research pipeline card: 119 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.